Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence

Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab

(2018) F. S. Macaluso et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

(2018) W. Yacoub et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

(2018) A. Barré et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases

(2018) Fabio Salvatore Macaluso et al.   DIGESTIVE AND LIVER DISEASE

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series

(2018) Lydia C T Buer et al.   INFLAMMATORY BOWEL DISEASES

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

(2017) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn’s Disease and Ulcerative Colitis

(2017) Maja Noman et al.   Journal of Crohns & Colitis

Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease

(2017) Maria Rosario et al.   Journal of Crohns & Colitis

Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis

(2017) Tal Engel et al.   Journal of Crohns & Colitis

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis

(2016) Shailja C. Shah et al.   Clinical Gastroenterology and Hepatology

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

(2016) Alessandro Armuzzi et al.   DIGESTIVE AND LIVER DISEASE

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge

(2016) Julia Salleron et al.   Journal of Crohns & Colitis

Long-term Efficacy of Vedolizumab for Crohn’s Disease

(2016) Severine Vermeire et al.   Journal of Crohns & Colitis

Long-term Efficacy of Vedolizumab for Ulcerative Colitis

(2016) Edward V. Loftus et al.   Journal of Crohns & Colitis

Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease

(2015) S. C. Shah et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed

(2015) J. P. Gisbert et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn’s Disease

(2015) Robert Hirten et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

(2015) Emily E. Vivio et al.   Journal of Crohns & Colitis

PRISMA—Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases

(2015) Man Cai Wang et al.   MEDICINE

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

(2014) Daniel Baumgart et al.   Drug Design Development and Therapy

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Leukocyte Trafficking in Inflammatory Bowel Disease

(2013) Fabio Cominelli   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology

Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

(2012) Amit Desai et al.   INFLAMMATORY BOWEL DISEASES

Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy

(2011) S. Danese et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: loss of response to anti-TNF treatments in Crohn’s disease

(2011) S. Ben-Horin et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Recommendations for the treatment of Crohnʼs disease with tumor necrosis factor antagonists: An expert consensus report

(2011) Brian G. Feagan et al.   INFLAMMATORY BOWEL DISEASES

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

(2010) Mario Cottone et al.   Clinical Gastroenterology and Hepatology

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease☆

(2010) Ambrogio Orlando et al.   DIGESTIVE AND LIVER DISEASE

Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease

(2010) Gionata Fiorino et al.   Expert Review of Clinical Immunology

Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy

(2010) H. Sokol et al.   GUT

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE